UBS Group
IPHA

UBS Group’s Innate Pharma IPHA Stock Holding History

UBS Group’s Portfolio IPHA Stock Details IPHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.1K Sell
861
-86
-9% -$140 ﹤0.01% 9623
2025
Q4 		$1.66K Sell
947
-3,850
-80% -$7.43K ﹤0.01% 9509
2025
Q3 		$9.26K Sell
4,797
-1,160
-19% -$2.33K ﹤0.01% 8613
2025
Q2 		$10.8K Sell
5,957
-3,044
-34% -$6.18K ﹤0.01% 8817
2025
Q1 		$16K Buy
9,001
+5,491
+156% +$10.7K ﹤0.01% 8370
2024
Q4 		$6.46K Sell
3,510
-4,898
-58% -$9.2K ﹤0.01% 8560
2024
Q3 		$19.3K Buy
8,408
+8,111
+2,731% +$17.9K ﹤0.01% 7397
2024
Q2 		$576 Buy
297
+87
+41% +$219 ﹤0.01% 8858
2024
Q1 		$604 Buy
210
+64
+44% +$168 ﹤0.01% 8453
2023
Q4 		$409 Hold
146
– – ﹤0.01% 8676
2023
Q3 		$369 Hold
146
– – ﹤0.01% 8546
2023
Q2 		$449 Sell
146
-1,113
-88% -$3.42K ﹤0.01% 8231
2023
Q1 		$3.59K Buy
1,259
+1,113
+762% +$3.58K ﹤0.01% 8298
2022
Q4 		$545 Sell
146
-4,359
-97% -$9.93K ﹤0.01% 10138
2022
Q3 		$9K Buy
4,505
+1,549
+52% +$4.18K ﹤0.01% 8579
2022
Q2 		$8K Buy
+2,956
New +$8.6K ﹤0.01% 8315

Other funds holding IPHA

LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

UBS Group's IPHA Position: Q1 2026 in Review

UBS Group reduced its Innate Pharma (IPHA) stake by 9.1% in Q1 2026, selling an estimated $140 and leaving 861 shares worth $1.1K. The position accounts for ﹤0.01% of the portfolio, ranked #9623.

UBS Group first reported a position in IPHA in Q2 2022 and has held it in 16 quarters since. The position peaked at $19.3K in Q3 2024. 9 funds tracked by Wall St. Rank hold IPHA as of Q1 2026.

  • UBS Group held 861 shares of Innate Pharma worth $1.1K as of Q1 2026.
  • UBS Group sold 86 Innate Pharma shares in Q1 2026, an estimated $140.
  • Innate Pharma made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9623 holding.
  • UBS Group first reported a position in Innate Pharma in Q2 2022 and has held it in 16 quarters since.
  • UBS Group's Innate Pharma position peaked at $19.3K in Q3 2024.
  • 9 funds tracked by Wall St. Rank held Innate Pharma as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.